# Michael Boretti

> Michael Boretti is the Chief Business Officer of Solu Therapeutics, a Boston biotech building a new class of cell-killing medicines on its CyTaC (Cytotoxicity Targeting Chimera) platform licensed from GSK. A bioengineer-turned-dealmaker with roughly two decades in biopharma, Boretti leads business development, strategic financing and alliance management. His earlier stops include CBO of Celsius Therapeutics, VP of Business Development at Epizyme, and VP of Corporate Development and Alliance Management at AVEO Oncology, where he helped shape partnerships with Astellas, Novartis and Janssen. He holds a B.S. in engineering science from the University of Virginia and a Ph.D. in bioengineering from the University of Pennsylvania.

- **Role:** Chief Business Officer at Solu Therapeutics
- **Organizations:** Solu Therapeutics, Celsius Therapeutics, Epizyme, AVEO Oncology, L.E.K. Consulting
- **Nationality:** American
- **Education:** B.S., Engineering Science, University of Virginia, Ph.D., Bioengineering, University of Pennsylvania
- **Known for:** Appointed Chief Business Officer of Solu Therapeutics in March 2024, Helped form AVEO Oncology's co-development/co-commercialization alliance with Astellas, recipient of the Scrip 2011 Licensing Deal of the Year Award, Drove partnerships around AVEO clinical and discovery-stage programs including transactions with Novartis, Janssen and Astellas

## Career timeline

- **Early career** — Began in life science consulting at L.E.K. Consulting after earning his Ph.D.
- **AVEO Oncology** — Rose to VP, Corporate Development and Alliance Management, driving partnerships with Astellas, Novartis and Janssen
- **Epizyme** — VP, Business Development - sourcing, structuring and negotiating strategic alliances for clinical pipelines, discovery programs and platforms
- **Celsius Therapeutics** — Chief Business Officer overseeing business development, alliance management, finance, communications, legal and IT
- **2024** — Appointed Chief Business Officer of Solu Therapeutics on March 19-20, 2024

## Achievements

- Appointed Chief Business Officer of Solu Therapeutics in March 2024
- Helped form AVEO Oncology's co-development/co-commercialization alliance with Astellas, recipient of the Scrip 2011 Licensing Deal of the Year Award
- Drove partnerships around AVEO clinical and discovery-stage programs including transactions with Novartis, Janssen and Astellas
- Built and managed strategic alliances at Epizyme (including work tied to Boehringer Ingelheim and Roche)
- Brings roughly 20 years of biotechnology leadership across diverse deal structures, asset stages and therapeutic areas

## Latest updates

- **2024-03** — Named Chief Business Officer of Solu Therapeutics to lead business development, strategic financing and alliance management.
- **2025-04** — Solu Therapeutics' funding profile reflects a Series A round; company total funding reported around $72M.

## Links

- Website: https://solutherapeutics.com
- LinkedIn: http://www.linkedin.com/in/michael-boretti-3715255

---

Profile page: https://yespress.io/michael-boretti
Published by YesPress — https://yespress.io
Last updated: 2026-06-10